Economics, University of California, Berkeley, United States.
Med Hypotheses. 2018 Feb;111:73-81. doi: 10.1016/j.mehy.2017.12.027. Epub 2017 Dec 30.
Androgenic alopecia, also known as pattern hair loss, is a chronic progressive condition that affects 80% of men and 50% of women throughout a lifetime. But despite its prevalence and extensive study, a coherent pathology model describing androgenic alopecia's precursors, biological step-processes, and physiological responses does not yet exist. While consensus is that androgenic alopecia is genetic and androgen-mediated by dihydrotestosterone, questions remain regarding dihydrotestosterone's exact role in androgenic alopecia onset. What causes dihydrotestosterone to increase in androgenic alopecia-prone tissues? By which mechanisms does dihydrotestosterone miniaturize androgenic alopecia-prone hair follicles? Why is dihydrotestosterone also associated with hair growth in secondary body and facial hair? Why does castration (which decreases androgen production by 95%) stop pattern hair loss, but not fully reverse it? Is there a relationship between dihydrotestosterone and tissue remodeling observed alongside androgenic alopecia onset? We review evidence supporting and challenging dihydrotestosterone's causal relationship with androgenic alopecia, then propose an evidence-based pathogenesis model that attempts to answer the above questions, account for additionally-suspected androgenic alopecia mediators, identify rate-limiting recovery factors, and elucidate better treatment targets. The hypothesis argues that: (1) chronic scalp tension transmitted from the galea aponeurotica induces an inflammatory response in androgenic alopecia-prone tissues; (2) dihydrotestosterone increases in androgenic alopecia-prone tissues as part of this inflammatory response; and (3) dihydrotestosterone does not directly miniaturize hair follicles. Rather, dihydrotestosterone is a co-mediator of tissue dermal sheath thickening, perifollicular fibrosis, and calcification - three chronic, progressive conditions concomitant with androgenic alopecia progression. These conditions remodel androgenic alopecia-prone tissues - restricting follicle growth space, oxygen, and nutrient supply - leading to the slow, persistent hair follicle miniaturization characterized in androgenic alopecia. If true, this hypothetical model explains the mechanisms by which dihydrotestosterone miniaturizes androgenic alopecia-prone hair follicles, describes a rationale for androgenic alopecia progression and patterning, makes sense of dihydrotestosterone's paradoxical role in hair loss and hair growth, and identifies targets to further improve androgenic alopecia recovery rates: fibrosis, calcification, and chronic scalp tension.
雄激素性脱发,又称模式性脱发,是一种慢性进行性疾病,影响一生中 80%的男性和 50%的女性。尽管它很普遍,并且已经进行了广泛的研究,但还没有一个连贯的病理学模型来描述雄激素性脱发的前驱期、生物学步骤过程和生理反应。虽然人们普遍认为雄激素性脱发是遗传的,并且是由二氢睾酮介导的,但关于二氢睾酮在雄激素性脱发发病中的确切作用仍存在疑问。是什么导致二氢睾酮在易患雄激素性脱发的组织中增加?二氢睾酮通过哪些机制使易患雄激素性脱发的毛囊缩小?为什么二氢睾酮也与身体其他部位和面部的二次毛发的生长有关?为什么去势(可使雄激素产生减少 95%)可以阻止模式性脱发,但不能完全逆转?二氢睾酮与观察到的与雄激素性脱发发病相关的组织重塑之间是否存在关系?我们回顾了支持和挑战二氢睾酮与雄激素性脱发因果关系的证据,然后提出了一个基于证据的发病机制模型,试图回答上述问题,解释另外怀疑的雄激素性脱发介质,确定限速恢复因素,并阐明更好的治疗靶点。该假说认为:(1)从腱膜下间隙传递到头皮的慢性头皮张力会在易患雄激素性脱发的组织中引起炎症反应;(2)二氢睾酮在易患雄激素性脱发的组织中增加,作为炎症反应的一部分;(3)二氢睾酮不会直接使毛囊缩小。相反,二氢睾酮是真皮鞘增厚、毛囊周围纤维化和钙化的共同介质,这三种慢性进行性疾病与雄激素性脱发的进展同时发生。这些情况重塑了易患雄激素性脱发的组织,限制了毛囊的生长空间、氧气和营养供应,导致雄激素性脱发特征性的缓慢、持续的毛囊缩小。如果这是真的,这个假设模型解释了二氢睾酮使易患雄激素性脱发的毛囊缩小的机制,描述了雄激素性脱发进展和模式形成的原理,解释了二氢睾酮在脱发和毛发生长中的矛盾作用,并确定了进一步提高雄激素性脱发恢复率的目标:纤维化、钙化和慢性头皮张力。